Delivered-To: tjphuhs@gmail.com Received: by 2002:adf:f3cb:0:b0:441:282b:bd with SMTP id g11csp1598060wrp; Fri, 24 Apr 2026 10:18:12 -0700 (PDT) X-Received: by 2002:ac8:6907:0:b0:509:2b02:c1bd with SMTP id d75a77b69052e-50e36825b23mr483906921cf.12.1777051091945; Fri, 24 Apr 2026 10:18:11 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1777051091; cv=none; d=google.com; s=arc-20240605; b=DcEnIHILNjpR7jCNBBGcxC8bdjqoPCDirtTSGdU0StYIu28axhdGaULfoloPUfVRSj RqxYHrPDH5EI9RMeAOQWOXH2eSHh80W4aQTxz1lizSUWC/OWrDxc/p3AXK4PJ4bM5uun i1zDm8I8yDs+lpvzr0vutST8/88fEZ9Wx31pvSM5HBtvOWe+D1G52KUyqSxIG/4m7GJa JB4AXi0Zy0XISd+cBcbIlwz4cUvZIU+fIWCe2J9/p3ZFF3vgUBgYGya8GrbU0YtP3KpX t3TAzP+07ni9KEXMAMr/XL9BlCSYbogUKfMNgTdQ4NNj5gTWXM4TpvhxKO35UapW0+zR O/gQ== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=list-unsubscribe-post:list-unsubscribe:list-post:list-id :list-archive:list-url:list-owner:reply-to:in-reply-to:references :sender:feedback-id:date:message-id:to:from:subject:mime-version :dkim-signature:dkim-signature; bh=nHu/LqKjvTwvRZavBaJ6qIHlU3BTrm8a3l+QMWox5bc=; fh=9zP21OW67FFZD2VV42mGudo540Qp4aalMWxJB5kMYug=; b=WicECljmtozCmyMulkvUnTNo4aoxLMEJL+sf5rjNvpxjtleMDAIxqOnA7Av/NnCG63 lXN5aULAYsojUHq2mNsehBSlaPjfBKnbJeq12sVKIY+6N1jNxRbAsMeeVbsxh9f6QIAG hMSLuNzngv8DrQkLZ7BJ9PzJCq0ydBEMJdnSFz4z0w4OEB74CLLTqkVqB0Lp5l/GhEMx p6sA0sggVSBiYneGID5Nqs3tQ//LiiQOXF/D4PkMsWeu1/XTcJiqakz2cUhS7Z21qGr+ +1s8Q8d5r14Eh0BBaWi69/P3jwnqp/OZBToUE28pxI5gieToB7JgWOXwQRUBt/z8xQio yUFA==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@mg-d1.substack.com header.s=k1 header.b="OmPvR5/L"; dkim=pass header.i=@mailgun.org header.s=mg header.b=lONB+Drs; spf=pass (google.com: domain of bounce+30b528.39b08c6-tjphuhs=gmail.com@mg-d1.substack.com designates 159.112.244.31 as permitted sender) smtp.mailfrom="bounce+30b528.39b08c6-tjphuhs=gmail.com@mg-d1.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com Return-Path: Received: from v531.v5375b7fa.use4.send.mailgun.net (v531.v5375b7fa.use4.send.mailgun.net. [159.112.244.31]) by mx.google.com with UTF8SMTPS id d75a77b69052e-50fbfafd614si106233271cf.383.2026.04.24.10.18.11 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Fri, 24 Apr 2026 10:18:11 -0700 (PDT) Received-SPF: pass (google.com: domain of bounce+30b528.39b08c6-tjphuhs=gmail.com@mg-d1.substack.com designates 159.112.244.31 as permitted sender) client-ip=159.112.244.31; Authentication-Results: mx.google.com; dkim=pass header.i=@mg-d1.substack.com header.s=k1 header.b="OmPvR5/L"; dkim=pass header.i=@mailgun.org header.s=mg header.b=lONB+Drs; spf=pass (google.com: domain of bounce+30b528.39b08c6-tjphuhs=gmail.com@mg-d1.substack.com designates 159.112.244.31 as permitted sender) smtp.mailfrom="bounce+30b528.39b08c6-tjphuhs=gmail.com@mg-d1.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mg-d1.substack.com; q=dns/txt; s=k1; t=1777051091; x=1777058291; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=nHu/LqKjvTwvRZavBaJ6qIHlU3BTrm8a3l+QMWox5bc=; b=OmPvR5/LMZXIseheoCShlp91Am9xR5xOx/Ffg3lHZ+ZVwF3FpUNikBknQF6XMUXf0n9NDxtV7C48HklfrcKTKdqGj6oLsyTOPFf6baMJl7fd0CtMJ3pO+PLRWMd+xxmpoL2U1ai0vMuxGyzN+ojWjez2ZT8lHet+IDPjrjEBLlk= DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mailgun.org; q=dns/txt; s=mg; t=1777051091; x=1777058291; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=nHu/LqKjvTwvRZavBaJ6qIHlU3BTrm8a3l+QMWox5bc=; b=lONB+DrsEF+18I08Fb/nlC1LBBkAXsUZkB2dJL2dZ++VN8B8XyJ7WttqtPJXWAW2Lgu9el6FuXU6IL5MH2v/lPn8QIgLbdXe36x4XtkQQM7i234rFkFKnZu/+eqf2WYzbBnp+rjEsy2DF8hQbHhHHxnvj0QmeD21E7DZhkA30WQ= X-Mailgun-Sid: WyIxMWU0ZSIsInRqcGh1aHNAZ21haWwuY29tIiwiMzliMDhjNiJd X-Feedback-Id: postmaster@mg-d1.substack.com:post:614a1297c57bbbe25fa40e08:mailgun Received: by 7f59c34a39f3e7d95f54fd5ce0d836e44b8541fab17c932ff82ad97ea8618bbb with HTTP id 69eba5d37723a59b5c2b3efe; Fri, 24 Apr 2026 17:18:11 GMT X-Mailgun-Sending-Ip: 159.112.244.31 Mime-Version: 1.0 Content-Type: multipart/alternative; boundary="c4e1e718c3d8c0e9dcb04ae46cb336bc42a427fd12fbf49139725fcaf046" Subject: MOTS-c vs NAD+: The Beginner's Guide to Understanding Two Mitochondrial Research Compounds From: Derek from Research Radar To: tjphuhs@gmail.com X-Mailgun-Tag: post X-Mailgun-Track-Clicks: false Message-Id: <20260424171804.3.48c0d9c9f777b28c@mg-d1.substack.com> Date: Fri, 24 Apr 2026 17:18:04 +0000 Feedback-Id: post-195371196:cat-post:pub-3365367:substack Sender: Derek from Research Radar References: In-Reply-To: Reply-To: Derek from Research Radar List-Owner: List-Url: List-Archive: List-Id: List-Post: List-Unsubscribe: List-Unsubscribe-Post: List-Unsubscribe=One-Click X-Mailgun-Variables: {"category": "post", "email_generated_at": "1777051091368", "is_freemail": "true", "post_audience": "everyone", "post_id": "195371196", "post_type": "newsletter", "pub_community_enabled": "true", "publication_id": "3365367", "subdomain": "derekpruski", "user_id": "273622398"} --c4e1e718c3d8c0e9dcb04ae46cb336bc42a427fd12fbf49139725fcaf046 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable View this post on the web at https://derekpruski.substack.com/p/mots-c-vs-n= ad-the-beginners-guide I get a lot of questions about MOTS-c versus NAD+, and one of the most comm= on is which one research protocols should implement first. This post breaks down what each one actually does, how they differ, and giv= es you a simple decision tree to think through which one fits your research= interests. A note on framing: Everything here is strictly for research use only. These= compounds are not for human consumption. Nothing below is medical advice. = This is educational content to help you understand what the research litera= ture says about these molecules and how they function at the cellular level= =2E The 30-Second Version MOTS-c is a small peptide (16 amino acids) that mitochondria produce. Think= of it as a signaling molecule that tells cells to burn fuel more efficient= ly, improve insulin sensitivity, and handle metabolic stress better. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme =E2=80=94 a helper m= olecule cells use for hundreds of reactions, especially energy production a= nd DNA repair. It=E2=80=99s not a peptide. It=E2=80=99s a fundamental molec= ule every living cell needs to function. One is a signal. The other is fuel for the machinery. That distinction matt= ers. What Are Mitochondria, Really? Before going further, a quick primer because everything below depends on it= =2E Mitochondria are the energy factories inside nearly every cell. They take n= utrients and turn them into ATP, the energy currency cells actually use to = do work. They also handle other jobs: regulating cell death, managing calci= um, producing heat, and sending stress signals to the rest of the organism. With age, mitochondria get less efficient. They produce less ATP, more wast= e (reactive oxygen species), and their signaling gets noisier. A lot of wha= t gets called =E2=80=9Caging=E2=80=9D at the cellular level is really mitoc= hondrial decline. Both MOTS-c and NAD+ are studied for their effects on this system, but from= completely different angles. MOTS-c: The Mitochondrial Messenger MOTS-c stands for =E2=80=9CMitochondrial Open Reading Frame of the 12S rRNA= type-c.=E2=80=9D Mouthful, I know. Here=E2=80=99s what matters. Where it comes from. Unlike most peptides which are encoded in nuclear DNA,= MOTS-c is encoded in mitochondrial DNA. Mitochondria produce it themselves= =2E It belongs to a small class called m= itochondrial-derived peptides (MDPs). What the research shows: Activates AMPK, the master energy sensor in cells. When AMPK is active, cel= ls shift into =E2=80=9Cburn fuel, don=E2=80=99t store it=E2=80=9D mode. Improves insulin sensitivity in preclinical models, meaning muscle cells pu= ll glucose out of circulation more efficiently. Appears to protect against metabolic stress in rodent studies (high-fat die= t models). Levels naturally decline with age, which some researchers think contributes= to age-related metabolic dysfunction. Mechanism in one sentence: MOTS-c is a signal that tells cells to burn fuel= efficiently and handle metabolic stress better. NAD+: The Universal Coenzyme NAD+ isn=E2=80=99t a peptide. It=E2=80=99s a dinucleotide =E2=80=94 a small= molecule that every cell uses constantly. Life isn=E2=80=99t possible with= out it. Where it comes from. Cells synthesize NAD+ continuously and recycle it thou= sands of times a day. Unlike MOTS-c, which is a targeted signaling peptide,= NAD+ is involved in a huge range of cellular processes at once. What the research shows: Required for the electron transport chain, the final step of ATP production= in mitochondria. Fuels sirtuins (SIRT1-7), a family of enzymes involved in DNA repair, gene = expression, and stress response. Required for PARP enzymes, which repair DNA damage. Levels drop significantly with age =E2=80=94 some research shows 50%+ decli= ne by middle age. Studied heavily in longevity, neuroprotection, and recovery-related literat= ure. Mechanism in one sentence: NAD+ is the coenzyme that powers energy producti= on, DNA repair, and longevity-related enzyme pathways. The Key Differences at a Glance MOTS-c is a signal. NAD+ is substrate. A thermostat versus the fuel in the = furnace. MOTS-c tells the system what to do. NAD+ is what the system uses t= o do it. MOTS-c targets metabolism specifically. Insulin sensitivity, glucose handli= ng, AMPK signaling. NAD+ touches almost everything cells do, which makes it= broader but also less targeted. MOTS-c is a peptide. NAD+ is a coenzyme. Totally different classes of molec= ules. MOTS-c research is relatively young. Discovered in 2015. The literature is = growing but still thin compared to NAD+, which has been studied since the e= arly 1900s. The Decision Tree Here=E2=80=99s a walkthrough to help you think about which direction matche= s your research interests. Read through top to bottom, stop at the first qu= estion where the answer is yes. 1. Is your focus primarily metabolic pathways? (glucose handling, insulin s= ensitivity, AMPK signaling) =E2=86=92 MOTS-c is more targeted. Focus area: AMPK activation literature. = Key models: high-fat diet rodent studies. 2. Is your focus primarily general cellular energy pathways? (ATP productio= n, mitochondrial function broadly) =E2=86=92 NAD+ sits upstream of energy production. Focus area: electron tra= nsport chain. Key models: age-related NAD+ decline studies. 3. Is your focus primarily longevity, DNA repair, or sirtuin biology? =E2=86=92 NAD+ is the direct play here. MOTS-c doesn=E2=80=99t directly fee= d these pathways. Focus area: SIRT1-7, PARP enzymes. 4. Is your focus primarily metabolic stress response? (how cells respond to= nutrient overload or metabolic challenge) =E2=86=92 MOTS-c has specific literature here. Focus area: mitochondrial-de= rived peptide signaling. 5. Broad mitochondrial interest without a specific target yet? =E2=86=92 NAD+ has a larger body of literature to start with. MOTS-c become= s a more targeted follow-up once the research question gets sharper. Common Beginner Questions Do MOTS-c and NAD+ overlap in mechanism? Not directly. MOTS-c activates AMPK signaling, which is a metabolic switch.= NAD+ is a coenzyme that powers entirely different enzyme families (sirtuin= s, PARPs) and sits at the core of ATP production. Both end up touching =E2= =80=9Cmitochondrial function,=E2=80=9D but through different doors. That=E2= =80=99s why the research questions they fit are different. Which one has stronger preclinical evidence? NAD+ has a much longer and broader literature =E2=80=94 it=E2=80=99s been s= tudied for over a century, and the age-related decline data is well replica= ted. MOTS-c is newer (2015 discovery) and the literature is narrower, but t= he AMPK and insulin sensitivity findings in rodent models have been replica= ted by multiple groups. Different maturity levels, both with interesting da= ta. Why do I see both called =E2=80=9Canti-aging=E2=80=9D? Because mitochondrial decline is one of the hallmarks of aging, and both co= mpounds intersect with that decline =E2=80=94 just at different points. MOT= S-c at the signaling layer, NAD+ at the substrate layer. The =E2=80=9Canti-= aging=E2=80=9D framing in marketing is usually oversimplified. The research= is more nuanced and mostly preclinical. Can they be studied together? Mechanistically they don=E2=80=99t conflict, and there=E2=80=99s some theor= etical rationale for why they might be complementary (signal plus substrate= ). But from a research design standpoint, studying both at once means you c= an=E2=80=99t tell which compound is driving any observed effect. One variab= le at a time is cleaner. Study one, document carefully, then consider the o= ther. What should I read first before getting deeper into either? For MOTS-c: the original 2015 Lee et al. paper in Cell Metabolism is the fo= undational read. For NAD+: the broader sirtuin literature and mitochondrial= bioenergetics reviews are good starting points. Get familiar with the mech= anisms before getting into protocol debates. The Honest Take Neither of these is a magic bullet. The research on both is genuinely inter= esting, but a lot of the marketing around them is ahead of the evidence. If you=E2=80=99re new and trying to decide where to focus, get very clear a= bout what you=E2=80=99re actually trying to study. =E2=80=9CEnergy=E2=80=9D= is too vague. =E2=80=9CAMPK signaling in the context of metabolic stress= =E2=80=9D or =E2=80=9Csirtuin activity in age-related cellular decline=E2= =80=9D is specific enough to tell which compound=E2=80=99s literature makes= more sense to dig into. The worst version of research is grabbing whatever=E2=80=99s on sale and ho= ping something happens. The best version is picking one compound, getting f= amiliar with the actual mechanism, and building a research question narrow = enough that the data you collect can actually answer it. Pick the one that matches your question. That=E2=80=99s how you actually le= arn. If this was useful, consider subscribing =E2=80=94 I publish breakdowns lik= e this regularly, along with vendor vetting notes, COA walkthroughs, and ne= w research summaries. Research use only. Not for human consumption. Educational content covering = what the scientific literature says about these compounds. Always verify CO= As on anything you source and stick to vetted vendors with third-party test= ing. Unsubscribe https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXN= raS5zdWJzdGFjay5jb20vYWN0aW9uL2Rpc2FibGVfZW1haWw_dG9rZW49ZXlKMWMyVnlYMmxrSW= pveU56TTJNakl6T1Rnc0luQnZjM1JmYVdRaU9qRTVOVE0zTVRFNU5pd2lhV0YwSWpveE56YzNNR= FV4TURreExDSmxlSEFpT2pFNE1EZzFPRGN3T1RFc0ltbHpjeUk2SW5CMVlpMHpNelkxTXpZM0lp= d2ljM1ZpSWpvaVpHbHpZV0pzWlY5bGJXRnBiQ0o5Lkw5X3R6QkZ2Q0FNeWo1R3pXNFN3blpNVF8= wV01idGNUcktaZ0JJcElVcDAiLCJwIjoxOTUzNzExOTYsInMiOjMzNjUzNjcsImYiOnRydWUsIn= UiOjI3MzYyMjM5OCwiaWF0IjoxNzc3MDUxMDkxLCJleHAiOjIwOTI2MjcwOTEsImlzcyI6InB1Y= i0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9.sKVhAKGx7SUcmSuwff5spcsRjMjTs-hXo5sH944= 2Tg8? --c4e1e718c3d8c0e9dcb04ae46cb336bc42a427fd12fbf49139725fcaf046 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable = MOTS-c vs NAD+: The Beginner's Guide to Understanding Two Mitochondrial Res= earch Compounds=3D""
I get a lot of questions about MOTS-c versus N= AD+, and one of the most common is which one research protocols should impl= ement first.
͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­
=
Forwarded this email? Subscribe here for more

MOTS-c vs NAD+: The Be= ginner's Guide to Understanding Two Mitochondrial Research Compounds
Derek
 
= =
=
3D""
3D""
READ IN APP
 

I get a lot of questions about MOTS-c versus NAD+, and= one of the most common is which one research protocols should implement fi= rst.

This p= ost breaks down what each one actually does, how they differ, and gives you= a simple decision tree to think through which one fits your research inter= ests.

A note on framing: Everything here is strictly for research use only. These compou= nds are not for human consumption. Nothing below is medical advice. This is= educational content to help you understand what the research literature sa= ys about these molecules and how they function at the cellular level.

Upgrade to paid
=

The 30-Second Version

MOTS-c<= /strong> is a small peptide (16 amino acids) that mitochondria produc= e. Think of it as a signaling molecule that tells cells to burn fuel more e= fficiently, improve insulin sensitivity, and handle metabolic stress better= =2E

NAD+ (nicotinamide adenine = dinucleotide) is a coenzyme — a helper molecule cells use for hundred= s of reactions, especially energy production and DNA repair. It’s not= a peptide. It’s a fundamental molecule every living cell needs to fu= nction.

One is a signal. The other is fuel for the machinery.= That distinction matters.

What Are Mitochondria, = Really?

Before going further, a quick primer because every= thing below depends on it.

Mitochondria are the energy fact= ories inside nearly every cell. They take nutrients and turn them into ATP,= the energy currency cells actually use to do work. They also handle other = jobs: regulating cell death, managing calcium, producing heat, and sending = stress signals to the rest of the organism.

With age, mitoc= hondria get less efficient. They produce less ATP, more waste (reactive oxy= gen species), and their signaling gets noisier. A lot of what gets called &= #8220;aging” at the cellular level is really mitochondrial decline.

Both MOTS-c and NAD+ are studied for their effects on this s= ystem, but from completely different angles.

MOTS-c: The Mi= tochondrial Messenger

MOTS-c stands for “Mitochondri= al Open Reading Frame of the 12S rRNA type-c.” Mouthful, I know. Here= ’s what matters.

Where it comes from. Unlike most peptides which are encoded in nuclear DNA, MOTS-c is en= coded in mitochondrial DNA. Mitochondria produce it themselves. It belongs = to a small class called mitochondrial-derived peptides (MDPs).

What the research shows:

  • Acti= vates AMPK, the master energy sensor in cells. When AMPK is active, cells s= hift into “burn fuel, don’t store it” mode.

  • Improves insulin sensitivity i= n preclinical models, meaning muscle cells pull glucose out of circulation = more efficiently.

  • Appears to protect against metabolic stress in rodent studies (high-fat di= et models).

  • Level= s naturally decline with age, which some researchers think contributes to a= ge-related metabolic dysfunction.

Mechanism in one sentence: MOTS-c is a signa= l that tells cells to burn fuel efficiently and handle metabolic stress bet= ter.

NAD+: The Universal Coenzyme

<= p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-s= ize: 16px;">NAD+ isn’t a peptide. It’s a dinucleotide — a= small molecule that every cell uses constantly. Life isn’t possible = without it.

Where it comes from. Cel= ls synthesize NAD+ continuously and recycle it thousands of times a day. Un= like MOTS-c, which is a targeted signaling peptide, NAD+ is involved in a h= uge range of cellular processes at once.

Wha= t the research shows:

    <= li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;">

    Required for the electron = transport chain, the final step of ATP production in mitochondria.

    =

  • Fuels sirtuins (SIRT1-7),= a family of enzymes involved in DNA repair, gene expression, and stress re= sponse.

  • Required = for PARP enzymes, which repair DNA damage.

  • Levels drop significantly with age — some r= esearch shows 50%+ decline by middle age.

  • Studied heavily in longevity, neuroprotection, and= recovery-related literature.

Mechanism in one sentence: NAD+ is the coenzyme = that powers energy production, DNA repair, and longevity-related enzyme pat= hways.

The Key Differences at a Glance<= /h2>

MOTS-c is a signal. NAD+ is substrate. A thermostat versus the fuel in the furnace. MOTS-c tells the system wh= at to do. NAD+ is what the system uses to do it.

MOTS-c targets metabolism specifically. Insulin sensiti= vity, glucose handling, AMPK signaling. NAD+ touches almost everything cell= s do, which makes it broader but also less targeted.

MOTS-c is a peptide. NAD+ is a coenzyme. Totally di= fferent classes of molecules.

MOTS-c researc= h is relatively young. Discovered in 2015. The literature is= growing but still thin compared to NAD+, which has been studied since the = early 1900s.

The Decision Tree

Here= ’s a walkthrough to help you think about which direction matches your= research interests. Read through top to bottom, stop at the first question= where the answer is yes.

<= td style=3D"text-align: center;">
3D""

= 1. Is your focus primarily metabolic pathways? (g= lucose handling, insulin sensitivity, AMPK signaling)

= → MOTS-c is more targeted. Focus = area: AMPK activation literature. Key models: high-fat diet rodent studies.=

2. Is your focus primarily general cellular= energy pathways? (ATP production, mitochondrial = function broadly)

→ NAD+ si= ts upstream of energy production. Focus area: electron trans= port chain. Key models: age-related NAD+ decline studies.

3. Is your focus primarily longevity, DNA repair, or sirtuin = biology?

→ NAD+ is the = direct play here. MOTS-c doesn’t directly feed these p= athways. Focus area: SIRT1-7, PARP enzymes.

= 4. Is your focus primarily metabolic stress response? (how cells respond to nutrient overload or metabolic challenge)

→ MOTS-c has specific literature = here. Focus area: mitochondrial-derived peptide signaling.

5. Broad mitochondrial interest without a spe= cific target yet?

→ NAD= + has a larger body of literature to start with. MOTS-c beco= mes a more targeted follow-up once the research question gets sharper.

Common Beginner Questions

Do MO= TS-c and NAD+ overlap in mechanism?

Not directly. = MOTS-c activates AMPK signaling, which is a metabolic switch. NAD+ is a coe= nzyme that powers entirely different enzyme families (sirtuins, PARPs) and = sits at the core of ATP production. Both end up touching “mitochondri= al function,” but through different doors. That’s why the resea= rch questions they fit are different.

Which one has= stronger preclinical evidence?

NAD+ has a much lo= nger and broader literature — it’s been studied for over a cent= ury, and the age-related decline data is well replicated. MOTS-c is newer (= 2015 discovery) and the literature is narrower, but the AMPK and insulin se= nsitivity findings in rodent models have been replicated by multiple groups= =2E Different maturity levels, both wi= th interesting data.

Why do I see both called “anti-aging”?

Because mitochondrial decline is one of the hallmarks of aging, and = both compounds intersect with that decline — just at different points= =2E MOTS-c at the signaling layer, NAD+= at the substrate layer. The “an= ti-aging” framing in marketing is usually oversimplified. The researc= h is more nuanced and mostly preclinical.

Can they = be studied together?

Mechanistically they don̵= 7;t conflict, and there’s some theoretical rationale for why they mig= ht be complementary (signal plus substrate). But from a research design sta= ndpoint, studying both at once means you can’t tell which compound is= driving any observed effect. One variable at a time is cleaner. Study one,= document carefully, then consider the other.

What = should I read first before getting deeper into either?

For MOTS-c: the original 2015 Lee et al. paper in Cel= l Metabolism is the foundational read. For NAD+: the broader sir= tuin literature and mitochondrial bioenergetics reviews are good starting p= oints. Get familiar with the mechanisms before getting into protocol debate= s.

The Honest Take

Neither of these= is a magic bullet. The research on both is genuinely interesting, but a lo= t of the marketing around them is ahead of the evidence.

If you’re new and trying to decide where to focus, get very clear= about what you’re actually trying to study.<= span> “Energy” is too vague. “AMPK signaling in the conte= xt of metabolic stress” or “sirtuin activity in age-related cel= lular decline” is specific enough to tell which compound’s lite= rature makes more sense to dig into.

The worst versi= on of research is grabbing whatever’s on sale and hoping something ha= ppens. The best version is picking one compound, getting familiar with the = actual mechanism, and building a research question narrow enough that the d= ata you collect can actually answer it.

Pick the one that m= atches your question. That’s how you actually learn.

If this was useful, consider subscribing — I publish breakdowns lik= e this regularly, along with vendor vetting notes, COA walkthroughs, and ne= w research summaries.

Research use only. Not for h= uman consumption. Educational content covering what the scientific literatu= re says about these compounds. Always verify COAs on anything you source an= d stick to vetted vendors with third-party testing.

Upgrade to paid

You're currently a free subscriber to Research Radar. For the full= experience, upgrade your subscription.

Upgrade to paid

=
 
3D""Share
 
 
3D""Like
3D""Comment
<= /td>
3D""Restack
<= tbody>
 

© 2026 Derek Pruski
548 Mark= et Street PMB 72296, San Francisco, CA 94104
Unsubscribe

3D"Start

<= /td>
=3D""3D"" --c4e1e718c3d8c0e9dcb04ae46cb336bc42a427fd12fbf49139725fcaf046--